Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.
about
Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.Thymocyte expansion and maturation: crosstalk of CD44v6 on thymocytes and panCD44 on stroma cells.Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysisIndoleamine 2,3-dioxygenase 1 (IDO1) activity correlates with immune system abnormalities in multiple myeloma.OCTET-CY: a phase II study to investigate the efficacy of post-transplant cyclophosphamide as sole graft-versus-host prophylaxis after allogeneic peripheral blood stem cell transplantationA Phase II trial of autologous stem cell transplantation followed by mini-allogeneic stem cell transplantation for the treatment of multiple myeloma: an analysis of Eastern Cooperative Oncology Group ECOG E4A98 and E1A97In pursuit of the allo-immune response in multiple myeloma: where do we go from here?Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantation.In search of the optimal platform for Post-Allogeneic SCT immunotherapy in relapsed multiple myeloma: a systematic review.Comparative diagnostic performance of ¹⁸F-FDG PET/CT versus whole-body MRI for determination of remission status in multiple myeloma after stem cell transplantation.Diagnostic performance of whole-body MRI for the detection of persistent or relapsing disease in multiple myeloma after stem cell transplantation.Functional autoantibodies against SSX-2 and NY-ESO-1 in multiple myeloma patients after allogeneic stem cell transplantation.
P2860
Q33402680-CEB1B3C8-66A6-43FF-871B-2E8940FEF812Q33507242-90C86537-EED4-4580-BE81-882B038A5670Q35172500-148D47D9-F837-4341-84A6-0B37007484F1Q36526999-9D80662E-8966-4A64-9CE9-05876BCA648DQ36833808-EFF82398-A4BA-47DD-A4A8-113E7228B638Q37088191-7FD66028-2E77-4FA9-A11F-E752E52D6935Q37349835-FF9AD071-B7FC-4E08-8D59-8C7E8FC04FFEQ38704573-4E84FBA2-CC97-4E13-8CF0-7D49CD1FD42FQ39424061-59109F9A-76E7-4B12-8099-C0CFA9E4BDB5Q39425529-F594DD96-8B10-4DF6-A006-9EDF2F0DDEEBQ44627038-AF8248A4-18DE-41E3-9B32-FFC124000BEFQ47834399-148DABFF-5D56-4D96-8D86-7839ED8BD4DDQ54196483-13B3F9D9-D769-4A2F-B0F4-22D7D0892665
P2860
Mini-Midi-Maxi? How to harness the graft-versus-myeloma effect and target molecular remission after allogeneic stem cell transplantation.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mini-Midi-Maxi? How to harness ...... eic stem cell transplantation.
@en
type
label
Mini-Midi-Maxi? How to harness ...... eic stem cell transplantation.
@en
prefLabel
Mini-Midi-Maxi? How to harness ...... eic stem cell transplantation.
@en
P2860
P356
P1433
P1476
Mini-Midi-Maxi? How to harness ...... eic stem cell transplantation.
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.LEU.2404775
P577
2007-06-14T00:00:00Z
P5875
P6179
1003952442